Welcome to our dedicated page for ANAVEX LIFE SCIENCES SEC filings (Ticker: AVXL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ANAVEX LIFE SCIENCES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ANAVEX LIFE SCIENCES's regulatory disclosures and financial reporting.
PVG Asset Management Corporation and Patrick S. Adams are leading an activist proxy solicitation for the 2026 annual meeting of Anavex Life Sciences Corp.. They seek to replace the Company’s entire Board with six independent nominees — Patrick Adams, Jason Kolbert, Ralf von Ziegesar, Rene Mora, John Boris and Curtis Hogue — using a GOLD universal proxy card that will list both their nominees and the Company’s nominees.
The PVG group collectively owns 327,344 shares of Anavex common stock and plans to vote these shares for its slate. Each share is entitled to one vote, and stockholders may vote for up to six director nominees in total on the universal card. PVG states that it has complied with Rule 14a-19(a)(1) and intends to solicit holders representing at least 67% of the voting power. If one or more PVG nominees are elected, they will legally replace an equal number of incumbent directors and, subject to their fiduciary duties, intend to work with any remaining directors to seek to maximize stockholder value.
Anavex Life Sciences Corp. reports that on July 20, 2026 it submitted a Compliance Plan to the Listing Qualifications Department of The Nasdaq Stock Market to regain compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the SEC.
The company previously received a deficiency notification letter on May 20, 2026 because it did not timely file its Form 10-Q for the quarter ended March 31, 2026. The notice has no immediate effect on the listing of its common stock, which continues to trade on The Nasdaq Global Select Market under the symbol AVXL. Nasdaq staff is reviewing the Compliance Plan and may grant an extension if it is accepted; if not, the company can request a hearing before an independent Hearings Panel.
Anavex Life Sciences Corp. scheduled its 2026 Annual Meeting of Stockholders for September 24, 2026. The Board of Directors set July 31, 2026 as the record date, determining which stockholders are entitled to receive notice of and vote at the meeting.
The company also set revised timing guidelines for stockholder proposals and director nominations because the 2026 meeting will occur more than 30 days after the prior year’s meeting. Proposals and nominations received on or before July 10, 2026 will be considered submitted within a reasonable time before proxy materials are printed and mailed.
Anavex Life Sciences Corp. reported that Nasdaq has notified the company it is out of compliance with Nasdaq Listing Rule 5250(c)(1) because it did not file its Form 10‑Q for the quarter ended March 31, 2026 on time. The company’s shares remain listed on the Nasdaq Global Select Market and continue trading under the symbol AVXL.
Anavex has until July 20, 2026 to submit a plan explaining how it will regain compliance. If Nasdaq accepts the plan, it may allow up to 180 days from the Form 10‑Q due date, through November 16, 2026, for Anavex to file and cure the delinquency. If Nasdaq does not accept the plan, the company could face a delisting process, though it would be able to appeal to a Nasdaq Hearings Panel. Anavex states it is working to complete the Form 10‑Q and submit its compliance plan.
Anavex Life Sciences Corp. reported the departure of its Chief Operating Officer, Felix Lauscher, effective May 11, 2026, as part of a broader reorganization of duties following the appointment of Dr. Terrie Kellmeyer as Interim Chief Executive Officer. Lauscher had served as COO since March 1, 2026.
Under his employment agreement, he received a prorated portion of his $264,000 annual base salary. He had been granted 50,000 stock options; 45,833 were forfeited upon departure, while 4,167 options that vested on March 31, 2026 remain exercisable until August 9, 2026 at $4.69 per share under the company’s Omnibus Incentive Plan. In connection with his departure, he was offered an additional two weeks of compensation at his base salary level in exchange for signing and not revoking a general release.
ANAVEX LIFE SCIENCES CORP. Interim CEO Terrie Kellmeyer has filed an initial Form 3 showing holdings of stock options rather than recent trades. The filing lists three option grants over common stock: options covering 50,000 shares with an exercise price of $8.58 expiring on March 31, 2035; 7,500 shares at $5.36 expiring on February 20, 2034; and 46,668 shares at $7.21 expiring on November 30, 2033, all held directly.
Footnotes clarify vesting: the 50,000-share grant includes 35,001 fully vested options and 11,667 that vest in two substantially equal tranches on June 30, 2026 and September 30, 2026. The 7,500-share grant includes 2,500 fully vested options and 5,000 that vest in two equal tranches based on performance milestones. Another 50,000-share grant includes 25,000 fully vested options and 25,000 that will vest in two equal performance-based tranches.
Anavex Life Sciences Corp. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 by the prescribed May 11, 2026 due date. The delay is due to an independent Special Committee review after the termination of the prior CEO on April 30, 2026, and the appointment of an Interim CEO on May 4, 2026. The Company says the Special Committee and management are working to complete their review so the Form 10-Q can be filed.
Anavex Life Sciences Corp. reported a leadership change and a pending filing delay. A special committee of independent directors ended the employment of President and Chief Executive Officer Christopher Missling, PhD, for Cause under his employment agreement and asked him to resign from the Board.
The Board appointed Terrie Kellmeyer, PhD, a veteran drug development executive and former Senior Vice President of Clinical Development at Anavex, as Interim Chief Executive Officer effective May 4, 2026. Her compensation includes a $500,000 base salary, a target bonus equal to 30% of salary, a $150,000 signing bonus, and 200,000 stock options. The company also expects to file a Form 12b-25 to extend the deadline for its Form 10-Q for the quarter ended March 31, 2026.
ANAVEX LIFE SCIENCES CORP. director Axel Paeger filed an initial Form 3, which is a statement of beneficial ownership for company insiders. The filing shows no reported transactions, exercises, gifts, or restructurings and contains no derivative holdings or position details in this excerpt.
Anavex Life Sciences Corp ownership filing shows 0 shares beneficially owned by The Vanguard Group as amended. The filing explains an internal realignment within Vanguard that led certain subsidiaries to report separately in reliance on SEC Release No. 34-39538, and states Vanguard reports no beneficial ownership in this class.